Renal Replacement Therapy in Infants and Children With Hepatorenal Syndrome Awaiting Liver Transplantation: A Case-Control Study

被引:13
|
作者
Parsons, C. Elizabeth [1 ]
Nelson, Raoul [1 ]
Book, Linda S. [1 ]
Jensen, M. Kyle [1 ]
机构
[1] Univ Utah, Primary Childrens Hosp, Salt Lake City, UT USA
关键词
HEPATIC-FAILURE; HEMODIALYSIS; MANAGEMENT; OUTCOMES; ASCITES; DISEASE;
D O I
10.1002/lt.23987
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Limited data on short- and long-term outcomes of renal replacement therapy (RRT) in pediatric liver transplantation (LT) patients exist. We evaluated risk factors for RRT in pediatric LT recipients with hepatorenal syndrome (HRS) and described the outcomes. We performed a single-center, case-control study of LT recipients who required RRT for HRS from 1999 to 2011. Three controls who did not receive RRT were matched with each case on the basis of age, diagnosis, and LT date. We identified 8 recipients among 133 recipients of 152 LT cases [6%, 95% confidence interval=2%-10%; mean age=7.7 years, range=0.5-19.8 years) who required RRT before LT for HRS. Four patients were <1 year old and weighed 5.6 to 6.6 kg. Biliary atresia was the most common LT indication. Cases had higher Model for (Pediatric) End-Stage Liver Disease scores at listing (26 versus 16, P=0.01) and lower glomerular filtration rates (GFRs; 15 versus 102 mL/minute/1.73 m(2), P<0.001) at RRT initiation or LT. Ascites, gastrointestinal bleeding, and infections occurred more commonly among cases: (100% versus 54%, P=0.03; 100% versus 46%, P=0.01; and 88% versus 33%, P=0.01, respectively). Cases also experienced toxic vancomycin troughs more frequently (38% versus 0%, P=0.01) and received RRT for a median of 21 days (range=3-355 days). The case mortality rate was 37.5% (3/8 at 1, 26, and 346 days after LT) and 0% for controls. The 4 infants required 0 to 3 dialysis catheter replacements during RRT. Cases and controls had similar median follow-ups [3.2 years (range=1.5-7.6 years) versus 4.9 years (range=0.2-11 years), P=0.29]. After LT, they also had similar GFRs (83 versus 99 mL/minute/1.73 m(2) at 1 month, P=0.19; 80 versus 107 mL/minute/1.73 m(2) at 1 year, P>0.99; and 97 versus 114 mL/minute/1.73 m(2) at the most recent follow-up, P=0.09). The case survival rates were 75% and 63% at 1 month and 1 year, respectively; 4 cases required antihypertensives and diuretics 1 month after LT, but at the last follow-up, only 1 case required antihypertensive therapy, and none required diuretics. In conclusion, pediatric patients with HRS, including infants, benefit from RRT. Although HRS decreases survival, patients with HRS who undergo LT generally recover renal function within 1 month that persists during long-term follow-up. Liver Transpl 20:1468-1474, 2014. (c) 2014 AASLD.
引用
收藏
页码:1468 / 1474
页数:7
相关论文
共 50 条
  • [1] The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome
    Velez, Juan Carlos Q.
    Wong, Florence
    Reddy, K. Rajender
    Sanyal, Arun J.
    Vargas, Hugo E.
    Curry, Michael P.
    Gonzalez, Stevan A.
    Pappas, S. Chris
    Jamil, Khurram
    KIDNEY360, 2023, 4 (08): : 1030 - 1038
  • [2] Is renal replacement therapy necessary in deceased donor liver transplantation candidates with hepatorenal syndrome?: a 2-year experience at a high-volume center
    Park, Gil-Chun
    Hwang, Shin
    Jung, Dong-Hwan
    Song, Gi-Won
    Ahn, Chul-Soo
    Kim, Ki-Hun
    Moon, Deok-Bog
    Ha, Tae-Yong
    Yoon, Young-In
    Cho, Hui-Dong
    Kwon, Jae-Hyun
    Chung, Yong-Kyu
    Kang, Sang-Hyun
    Jung, I-Ji
    Choi, Jin Uk
    Lee, Sung-Gyu
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2020, 98 (02) : 102 - 109
  • [3] Living vs. Deceased Donor Liver Transplantation Provides Comparable Recovery of Renal Function in Patients With Hepatorenal Syndrome: A Matched Case-Control Study
    Goldaracena, N.
    Marquez, M.
    Selzner, N.
    Spetzler, V. N.
    Cattral, M. S.
    Greig, P. D.
    Lilly, L.
    McGilvray, I. D.
    Levy, G. A.
    Ghanekar, A.
    Renner, E. L.
    Grant, D. R.
    Selzner, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (12) : 2788 - 2795
  • [4] Intraoperative Renal Replacement Therapy in Orthotopic Liver Transplantation
    Bohorquez, Humberto
    Koyner, Jay L.
    Jones, Courtney R.
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2023, 30 (04): : 378 - 386
  • [5] Hepatopulmonary Syndrome and Post-Liver Transplantation Complications: A Case-Control Study
    Morvan, A.
    Gazon, M.
    Duperret, S.
    Schmitt, Z.
    Pradat, P.
    Mohkam, K.
    Aubrun, F.
    INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE, 2020, 11 (04): : 165 - 175
  • [6] Renal replacement therapy as bridging-to-recovery in refractory hepatorenal syndrome
    Luedemann, Christoph
    Plota, Jessica
    Nattermann, Jacob
    Strassburg, Christian P.
    Lutz, Philipp
    Goeser, Felix
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (04): : 331 - 335
  • [7] Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: A case-control study
    Alessandria, C.
    Debernardi-Venon, W.
    Carello, M.
    Ceretto, S.
    Rizzetto, A.
    Marzano, A.
    DIGESTIVE AND LIVER DISEASE, 2009, 41 (04) : 298 - 302
  • [8] Benefits of Intraoperative Continuous Renal Replacement Therapy During Liver Transplantation in Patients With Renal Dysfunction
    Baek, S. D.
    Jang, M.
    Kim, W.
    Yu, H.
    Hwang, S.
    Lee, S. -G.
    Hwang, G. -S.
    Lee, E. K.
    Kim, S. M.
    Chang, J. W.
    TRANSPLANTATION PROCEEDINGS, 2017, 49 (06) : 1344 - 1350
  • [9] Ex vivo reconstruction of the donor renal artery in renal transplantation: a case-control study
    McLoughlin, Louise C.
    Davis, Niall F.
    Dowling, Catherine M.
    Power, Richard E.
    Mohan, Ponnusamy
    Hickey, David P.
    Smyth, Gordon P.
    Eng, Molly M. P.
    Little, Dilly M.
    TRANSPLANT INTERNATIONAL, 2014, 27 (05) : 458 - 466
  • [10] Association of Hepatorenal Syndrome-Acute Kidney Injury with Mortality in Patients with Cirrhosis Requiring Renal Replacement Therapy
    Cama-Olivares, Augusto
    Ouyang, Tianqi
    Takeuchi, Tomonori
    St Hillien, Shelsea A.
    Robinson, Jevon E.
    Chung, Raymond T.
    Cullaro, Giuseppe
    Karvellas, Constantine J.
    Levitsky, Josh
    Orman, Eric S.
    Patidar, Kavish R.
    Regner, Kevin R.
    Saly, Danielle L.
    Sawinski, Deirdre
    Sharma, Pratima
    Teixeira, J. Pedro
    Ufere, Nneka N.
    Velez, Juan Carlos Q.
    Wadei, Hani M.
    Wahid, Nabeel
    Allegretti, Andrew S.
    Neyra, Javier A.
    Belcher, Justin M.
    HRS HARMONY Consortium
    KIDNEY360, 2025, 6 (02): : 247 - 256